Although BATF2 expression had no significant correlation with the gender, age, diagnosis or classification (Table S1), higher cytoplasmic BATF2 expression level was associated with poorer OS probability in CRC patients (p = .0003), both at stage I/II (p = .0246) and stage III/IV (p = .0028) (Figure 1H–J), while higher total or nuclear BATF2 expression was correlated with longer OS in CRC patients (p < .05) (Figure S2A–D). Here, BATF2 is linked to colorectal carcinoma.